---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-25-000009"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:51:39.874594+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro prelim Q4 rev record $8.2M, +30% YoY; Lonza collaboration

## Summary
- Q4 total revenue preliminary ~$8.2M (record), +30% YoY; recurring rev ~$4.2M, +27% YoY.
- FY 2024 total rev ~$28.1M, +25% YoY; recurring rev ~$15.5M, +14% YoY.
- Placed 6 new Growth Direct systems in Q4; 21 systems placed in FY 2024; cumulative >160 placed globally.
- Collaborated with Lonza to integrate Growth Direct with MODA-EM; Lonza deploying across global cell and gene therapy network.
- Preliminary results unaudited; final results and 2025 outlook expected later in Q1 2025.

## SEC filing metadata
- accession: 0001380106-25-000009
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010625000009/0001380106-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010625000009/rpid-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-25-000009
- JSON: https://secwatch.observer/filing/0001380106-25-000009.json
- Plain text: https://secwatch.observer/filing/0001380106-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.